News Agencies Feed :


    November 20, 2017

    Cancer Patients, Survivors, Supporters and Caregivers Undertake UAE's First Relay for Life

    (AETOS Wire)-- Sharjah, the third largest of the United Arab Emirate’s seven emirates, was the host for the MENA region’s first ever ‘Global Relay for Life,’ (RFL) a 24-hour walkathon that is the biggest fundraising event"...

    November 20, 2017

    Prime Hospital Reiterates Commitment Enhancing Healthcare Sector with Ultrasound-Guided Nerve Blocks

    Prime Hospital, one of the UAE’s leading healthcare service providers, has achieved another milestone by applying various innovative Anesthetic Techniques developed to bring pain relief to patients after surgery. This is"...

    November 19, 2017

    Emirates Hospital Reaffirms Commitment to Medical Tourism

    Emirates Hospital, a leading healthcare facility owned by KBBO Group, has reaffirmed its commitment to providing medical services to tourists, particularly Chinese visitors.

    During official visit and meeting with"...

    November 19, 2017

    NMC Healthcare to Speak At Milken Institute London Summit on Impact of AI on Healthcare Sector

    The growth operation and management (O&A) model in the healthcare sector will enable healthcare providers around the world to offer patients better services, according to the CEO of the region’s leading healthcare groups, NMC Healthcare.


    November 19, 2017

    New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatment of EGFR-mutated Non-small Cell Lung Cancer

    (AETOS Wire)-- AstraZeneca today announced that the New England Journal of Medicine has published the positive results from the Phase III FLAURA trial which provide data for Tagrisso’s (osimertinib) use in the 1st-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).1 The trial showed a statistically significant, clinically meaningful progression-free survival (PFS) advantage for osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), compared with current 1st-line EGFR-TKIs, erlotinib or gefitinib.1 Dr. Suresh......

    November 19, 2017

    New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases

    (AETOS Wire) -- AstraZeneca today presented new data from a subgroup analysis of the Phase III FLAURA trial, which explored osimertinib as 1st-line therapy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive"...

    November 15, 2017

    Macrogen Corp.'s Clinical NGS Laboratory Receives CAP Accreditation

    (AETOS Wire)-- Macrogen Corp. ( announces that its Clinical Lab that provides clinical NGS services has been awarded accreditation by the Accreditation Committee of the College of American Pathologists (CAP) based on results of a recent on-site inspection as part of the CAP’s Accreditation Programs. “Macrogen demonstrates leadership, innovation, and a passionate commitment to standards of excellence while providing the highest quality services, ultimately for patients,” said Bharati Jhaveri, MD, FCAP, chair of the CAP’s Council on Accreditation. “The CAP congratulates Macrogen Corp. on its recent......

    November 15, 2017

    Key sub-analyses of RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if Pradaxa® (dabigatran etexilate) dual therapy was used instead of warfarin triple therapy

    • Dual therapy with dabigatran consistently favourable across key sub-groups in atrial fibrillation patients following PCI with stent placement
    • Benefits shown in sub-group analyses were consistent with overall results of the trial
    • Data presented at AHA Scientific Sessions 2017 reinforce safety benefits of dabigatran


    November 14, 2017

    New RE-VERSE AD™ analyses provide additional insights on impact of Praxbind® (idarucizumab) in Pradaxa® (dabigatran etexilate) patients with gastrointestinal bleeding or needing emergency surgery

    • Additional analyses of patients in diverse emergency settings confirm that idarucizumab immediately reverses the anticoagulant effect of dabigatran in patients in emergency settings1,2
    • Sub-analyses from RE-VERSE AD™, the largest study to investigate a reversal agent for a non-vitamin K antagonist oral anticoagulant (NOAC), presented...

    November 14, 2017

    Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease

    • Empagliflozin (marketed as Jardiance®) reduced the risk of cardiovascular death by 43 percent versus placebo in patients with type 2 diabetes and peripheral artery disease1
    • In a population at high risk for amputations, no increased risk in lower-limb amputation was observed with empagliflozin treatment1


    Stock Market






    10 285,00

    -0,17 %

    10 302,90


    12 597,29

    -0,19 %

    12 621,52


    11 868,45

    -0,26 %

    11 899,85

    Found articles: - Pages  
    Contact US | Powered by - All Rights Reserved